SiBone $SIBN Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC reduced its stake in shares of SiBone (NASDAQ:SIBN) by 45.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,991 shares of the company’s stock after selling 37,218 shares during the quarter. Sterling Capital Management LLC’s holdings in SiBone were worth $568,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after purchasing an additional 1,053 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in SiBone during the 1st quarter worth approximately $225,000. Goldman Sachs Group Inc. increased its position in SiBone by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after buying an additional 83,919 shares during the period. Jane Street Group LLC purchased a new stake in SiBone in the first quarter valued at approximately $1,818,000. Finally, Legal & General Group Plc lifted its stake in SiBone by 16.1% in the second quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock valued at $798,000 after buying an additional 5,888 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on SIBN shares. TD Cowen decreased their price target on shares of SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Wall Street Zen lowered SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Truist Financial restated a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

SiBone Stock Up 1.8%

SIBN stock opened at $17.11 on Friday. SiBone has a one year low of $11.48 and a one year high of $21.89. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.99. The company has a fifty day moving average of $14.64 and a 200-day moving average of $15.51. The stock has a market capitalization of $758.83 million, a PE ratio of -43.87 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The firm had revenue of $52.59 million during the quarter, compared to the consensus estimate of $51.16 million. As a group, analysts expect that SiBone will post -0.44 EPS for the current year.

Insiders Place Their Bets

In other SiBone news, Director Jeffrey W. Dunn sold 3,575 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $15.25, for a total value of $54,518.75. Following the completion of the sale, the director owned 16,057 shares of the company’s stock, valued at approximately $244,869.25. This trade represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy E. Davis, Jr. sold 3,500 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $14.14, for a total transaction of $49,490.00. Following the transaction, the director directly owned 65,722 shares in the company, valued at approximately $929,309.08. This trade represents a 5.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 29,875 shares of company stock worth $437,666 in the last ninety days. 4.00% of the stock is owned by insiders.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.